Australian pharmaceutical giant CSL announced a strategic overhaul including spinning off its vaccine subsidiary, Seqirus, into a standalone entity and cutting up to 15% of its workforce. The restructuring aims to save over $500 million annually by streamlining operations and fostering a more autonomous vaccine business amid intense market competition and global geopolitical complexities. Despite a slight revenue uptick, CSL’s leadership cited softness in U.S. influenza vaccine uptake as a major challenge. The vaccine spin-off is expected to complete by mid-2026, reflecting a significant reshaping of CSL’s corporate structure and cost base.